One RNASEL gene variant has been implicated in as much as 13% of prostate cancer cases, and men who are homozygous for the Arg46sGln allele mutation can exhibit double the risk of developing prostate cancer when compared to men who carry no RNASEL mutated alleles [66,67]. This evidence concerns the gene RNASEL and prostate cancer.